Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254408 · ClinicalTrials.gov registry record · Phase 2
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
NCT02254408 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 189 participants.
The verdict
NCT02254408, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV upper respiratory tract infection (URTI), the effect of presatovir on development of lower respiratory tract complication, being free of any supplemental oxygen progression to respiratory failure, and pharmacokinetics (PK), safety, and tolerability of presatovir.
Interventions
- DRUG Placebo
- DRUG Presatovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2015-01-23 |
| Est. Completion | 2017-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02254408
The ClinicalTrials.gov registry entry for NCT02254408 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02254408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02254408 about?
NCT02254408 is a clinical study titled "Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract". The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV upper respiratory tract infection (URTI), the effect of presatovir on development o...
What is the current status of trial NCT02254408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2015-01-23. Estimated completion is 2017-07-14.
What interventions are being tested in trial NCT02254408?
The interventions under investigation include: Placebo (DRUG), Presatovir (DRUG).
Who is sponsoring clinical trial NCT02254408?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.